JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

JNJ

224.47

-0.51%↓

UNH

366.96

+0.87%↑

TMO

472.13

+1.14%↑

ISRG

451.65

+0.02%↑

ABT

86.23

-1.07%↓

Kodu・Aktsiate loetelu・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Avatud

SektorTervishoid

4.68 0.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.55

Max

4.73

Põhinäitajad
By Trading Economics
Sissetulek	21M 61M
Müük	-74M 48M
P/E Sektori keskmine	28.688 67.147
Kasumimarginaal	128.703
Töötajad	100
EBITDA	-68M 8.8M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+117.86% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	146M 756M
Eelmine avamishind	4.47
Eelmine sulgemishind	4.68

Uudiste sentiment

By Acuity

50%

180 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

N/A / 0.9337 Toetus ja vastupanu

Ironwood Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. mai 2026, 23:43 UTC

Uudisväärsed sündmused

New Zealand's Unemployment Rate Falls in 1Q

5. mai 2026, 23:20 UTC

Kuumad aktsiad

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5. mai 2026, 21:48 UTC

Tulu

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5. mai 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6. mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5. mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5. mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5. mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5. mai 2026, 22:08 UTC

Tulu

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5. mai 2026, 22:07 UTC

Tulu

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Rev $1.2B >PAAS

5. mai 2026, 21:42 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:38 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:30 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:29 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:26 UTC

Tulu

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q EPS 39c >ALC.EB

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5. mai 2026, 21:24 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:18 UTC

Tulu

Mistras Backs 2026 Rev $730M-$750M >MG

5. mai 2026, 21:17 UTC

Tulu

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5. mai 2026, 21:15 UTC

Tulu

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5. mai 2026, 21:12 UTC

Tulu

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5. mai 2026, 21:11 UTC

Tulu

SSR Mining 1Q Rev $581.8M >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q Adj EPS $1.15 >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q EPS $1.16 >SSRM

5. mai 2026, 21:08 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:01 UTC

Tulu

Intact Financial 1Q EPS C$4.12 >IFC.T

5. mai 2026, 21:01 UTC

Kuumad aktsiad

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Võrdlus sarnastega

Hinnamuutus

Ironwood Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

117.86% tõus

12 kuu keskmine prognoos

Keskmine 10 USD 117.86%

Kõrge 10 USD

Madal 10 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Ironwood Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Ironwood Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 0.9337Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

All events are bearish.

Sentiment

By Acuity

180 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.